Three notes:
- The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson’s disease. Patients receiving the drug at doses of 5 milligrams and 15 milligrams showed significant reductions in the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale.
- In addition to the primary endpoint, the trial met key secondary endpoints, showing clinically meaningful movements in the motor aspects of daily living for both dose groups. This indicates the drug’s potential for enhancing the quality of life for individuals with early stage Parkinson’s, the release said.
- The safety profile of tevapadon was consistent with earlier studies, with most adverse events categorized as mild to to moderate. Results from the Tempo-2 trial are expected by the end of 2024.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
